IPSC - NASDAQ
Century Therapeutics, Inc.
$2.18
-0.34%Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live SnapshotCentury Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Century Therapeutics, Inc. Balance Sheet
IPSC • NASDAQ
| Century Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
61.9M | 58.4M | 47.3M | 84.3M | 56.4M | 27.2M | 44.1M | |
55.3M | 130.9M | 125.4M | 231.2M | 166.4M | 48.5M | 37.5M | |
117.1M | 189.3M | 172.7M | 315.5M | 222.9M | 75.8M | 81.5M | |
667K | 1.5M | 665K | 780K | 250K | 908K | 123K | |
0.0 | 1.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
667K | 0.0 | 665K | 780K | 250K | 908K | 123K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.3M | |
0.0 | 2.4M | 1.8M | 3M | 2.2M | 337K | 0.0 | |
3M | 860K | 1.8M | 462K | 2.8M | 1.8M | 2.5M | |
120.8M | 194.1M | 177M | 319.7M | 228.2M | 78.8M | 84.1M | |
NON-CURRENT ASSETS | |||||||
66.2M | 90.8M | 92.1M | 111.7M | 69.8M | 24.8M | 2.5M | |
34.2M | 34.2M | 0.0 | 0.0 | 0.0 | 9.4M | 0.0 | |
34.2M | 34.2M | 0.0 | 0.0 | 0.0 | 9.4M | 0.0 | |
2.4M | 30.8M | 91.1M | 51.9M | 135.9M | 1.1M | 4.1M | |
211K | 3.3M | 541K | 3.2M | 3.5M | -7.2M | 206K | |
102.9M | 159.2M | 183.7M | 166.8M | 209.2M | 28M | 6.8M | |
223.7M | 353.2M | 360.7M | 486.5M | 437.4M | 106.8M | 90.9M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
4.8M | 3.1M | 2.7M | 5.5M | 7.6M | 8.1M | 1.5M | |
4.8M | 3.1M | 2.7M | 5.5M | 7.6M | 8.1M | 1.5M | |
0.0 | 12.6M | 6.5M | 7.1M | 5.3M | 3.7M | 1.4M | |
3.3M | 0.0 | 1.5M | 6.5M | 1M | 0.0 | 0.0 | |
0.0 | 4.9M | 0.0 | 475K | 615K | 240K | 0.0 | |
0.0 | 109.2M | 4.4M | 7.2M | 0.0 | 0.0 | 0.0 | |
12.1M | 82K | 2.7M | 3.2M | 1.1M | 52K | 0.0 | |
20.2M | 129.8M | 17.8M | 29.8M | 15.7M | 12.1M | 3M | |
NON-CURRENT LIABILITIES | |||||||
0.0 | 0.0 | 0.0 | 3.7M | 8.9M | 9.6M | 0.0 | |
0.0 | 0.0 | 111.4M | 110.8M | 0.0 | 0.0 | 0.0 | |
4.3M | 4.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 8.7M | 56K | 718K | 2M | 179.8M | 0.0 | |
44.5M | 62.1M | 158.1M | 154M | 25.5M | 201.1M | 179.8M | |
40.2M | 53.8M | 46.7M | 39.2M | 15.2M | 11.9M | 0.0 | |
64.8M | 191.9M | 175.9M | 183.8M | 41.1M | 213.2M | 182.8M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 179.8M | |
9K | 9K | 6K | 6K | 5K | 1K | 1K | |
950.8M | 943.4M | 840.4M | 824.3M | 785M | 217.8M | 216.9M | |
-791.9M | -782.3M | -655.8M | -519.1M | -388.2M | -292.3M | -238.8M | |
30K | 324K | 108K | -2.5M | -650K | -3K | -3K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -31.9M | -70M | |
158.9M | 161.4M | 184.8M | 302.7M | 396.2M | -106.4M | -91.9M | |
158.9M | 161.4M | 184.8M | 302.7M | 396.2M | -106.4M | -91.9M | |
SUMMARY | |||||||
223.7M | 353.2M | 360.7M | 486.5M | 437.4M | 106.8M | 90.9M | |
57.6M | 161.7M | 216.5M | 283.1M | 302.3M | 49.6M | 41.6M | |
43.6M | 53.8M | 48.2M | 49.4M | 25.1M | 21.6M | 0.0 | |
-18.3M | -4.6M | 847K | -34.9M | -31.3M | -5.7M | -44.1M | |
86,387,476 | 86,387,476 | 86,387,476 | 86,387,476 | 86,387,476 | 86,387,476 | 86,387,476 |
SEC Filings
IPSC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | February 05, 2026 | February 05, 2026 | ||
8-K 8-K 2026 N/A | January 23, 2026 | January 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 |
Related Guides
Continue your IPSC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.